BioInvent Unveils Promising R/R NHL & CTCL Data at 31st EHA Congress – Boost for Antibody‑Based Therapies
BioInvent unveils early data on BI‑1206 and BI‑1808 at the European Hematology Congress, showing 80% ORR for rituximab‑resistant lymphoma and 50% ORR for CTCL, spotlighting breakthrough Fc?RIIB and TNFR2 antibody therapies.
3 minutes to read